The US Food and Drug Administration has approved Besponsa (inotuzumab ozogamicin), an antibody-drug conjugate, to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
